China: Market Report China's Pharmaceutical Equipment Market 2020: Current Status, Trends & Recommendations for Action
China is known as the country of large numbers – this also applies to the pharmaceutical industry there. With currently over 4,800 pharmaceutical producers, the Chinese market continues to offer huge opportunities for the global equipment industry. A recent ‘Vogel Market Insight Report’ shows that despite extensive attempts by local equipment companies to copy the Chinese market, the user industry cannot avoid Western high-tech equipment.
China – China's pharmaceutical industry is undergoing radical change. In order to strengthen the monitoring of the huge pharmaceutical market and significantly improve the quality of drugs, the Chinese Government has issued several new directives, including the ‘Two Invoice’ regulation and the ‘4+7 Drug Procurement with Target Quantity’ regulations. The aim: in addition to more quality, the efficiency and cost savings in the system are to be significantly increased.
But despite – or perhaps because of – the large numbers: The claim between top pharmaceutical products and the use of high-quality equipment technologies still often diverges in the 'Middle Kingdom', especially among local manufacturers. A recent report by PharmaTEC China (a trade publication of Vogel Communications Group) in cooperation with M2Consulting shows that China's pharmaceutical industry still cannot do without Western high-tech equipment and technologies.
Although many and varied copies and replicas are made, local high-tech is absolutely scarce, not least because of a lack of precision and this is despite the fact that the equipment segment already has around 1,000 companies. It is therefore hardly surprising that many of those returning from abroad as specialists of larger Chinese pharmaceutical manufacturers are familiar with Western quality technologies and want to continue to rely on them in the future. Smaller, purely local pharmaceutical manufacturers, on the other hand, still resort to replicas of a Chinese equipment industry that is by no means competitive internationally.
But as much as Western suppliers can score with technological precision technologies, they are apparently not very convincing when it comes to after-sales. "Chinese users in the pharmaceutical industry often perceive deficits as a shortcoming of Western technology providers. The results of the survey show that local suppliers with fast and efficient services can obviously score even better than the technology leaders from the West", emphasizes Jiaqi Zhu, Project Manager Market Insights at Vogel Communications Group.
The results of the study, however, illustrate the overall continuing high investment needs of pharmaceutical manufacturers – for example, with regard to capacity expansions in production, with a view to the required technologies as well as necessary measures for digitalisation. "Against this backdrop, global high-tech providers continue to have very good growth opportunities in China," Zhu says.
The 40-page report with many figures, graphics and recommendations for action is based on a large survey of users in the pharmaceutical industry in China and is aimed primarily at technology and equipment companies that have this growth market in mind. You can find further information and infographics at https://vogel-fachbuch.de/en/detail/index/sArticle/774/sCategory/226
This article is protected by copyright. You want to use it for your own purpose? Contact us at support.vogel.de (ID: 46575485)